Among the potential candidates, we focused our attention on NOX4 because it has been implicated in mediating TGF-β pro-tumorigenic effects on the TME, more specifically in CAF activation in several tumours.15 Furthermore, NOX4 inhibitors exist, are commercially available and are being tested at the clinical level in different settings. Here, TGFB1 is linked to neoplasm.